Free Trial
LON:PYC

Physiomics Final Earnings Report

Physiomics logo
GBX 0.62 +0.02 (+3.99%)
As of 06/8/2026 11:18 AM Eastern

Physiomics EPS Results

Actual EPS
-GBX 0.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Physiomics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Physiomics Announcement Details

Quarter
Final
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Physiomics Earnings Headlines

Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
ISS weighs in on Physiomics ahead of general meeting
AIM Market Roundup: Physiomics, Tern, Cleantech Lithium
See More Physiomics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Physiomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Physiomics and other key companies, straight to your email.

About Physiomics

Physiomics (LON:PYC) provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. The company was incorporated in 2001 and is based in Oxford, the United Kingdom.

View Physiomics Profile